Nutra Pharma Corp (NPHC) Payables (2010 - 2026)

Nutra Pharma has disclosed Payables across 17 years of filings, most recently posting $2.9 million for Q2 2026.

• In Q2 2026, Payables rose 70.34% year-over-year to $2.9 million; the TTM figure through Jun 2026 stood at $2.9 million (up 70.34% YoY), while the FY2025 annual figure was $1.8 million, up 20.1% from the prior year.
• Payables came in at $2.9 million for Q2 2026 at Nutra Pharma, up from $1.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.8 million in Q1 2022 to a low of $1.4 million in Q4 2022.
• Average Payables over 5 years is $2.5 million, with a median of $1.6 million recorded in 2024.
• Year-over-year, Payables slumped 87.89% in 2022 and jumped 70.34% in 2026.
• Over 5 years, Payables stood at $1.4 million in 2022, then climbed by 4.96% to $1.4 million in 2023, then grew by 6.05% to $1.5 million in 2024, then rose by 20.1% to $1.8 million in 2025, then jumped by 61.35% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $2.9 million in Q2 2026, $1.8 million in Q1 2026, and $1.8 million in Q4 2025.